10-Q: Creative Medical Technology Holdings Reports Third Quarter 2024 Results, Advances Clinical Programs

Creative Medical Technology Holdings reports a net loss of $1.04 million for the third quarter of 2024, while progressing its clinical trials and research programs.

Summary

• Creative Medical Technology Holdings reported a net loss of $1.04 million for the three months ended September 30, 2024, compared to a net loss of $1.45 million for the same period in 2023.
• The company's operating loss for the quarter was $1.11 million, an improvement from the $1.55 million loss in the prior year's quarter.
• For the nine months ended September 30, 2024, the net loss was $3.64 million, slightly higher than the $3.61 million loss in the same period of 2023.
• Revenue for the nine-month period was $8,000, compared to $6,000 in the prior year.
• Research and development expenses increased to $1.93 million for the nine months ended September 30, 2024, up from $1.62 million in the same period of 2023, primarily due to clinical trial costs.
• The company had $6.26 million in cash and cash equivalents as of September 30, 2024, compared to $3.47 million at the end of 2023.
• The company repurchased 43,750 shares of its common stock for $174,964 during the nine months ended September 30, 2024.
• The company completed a registered direct offering on October 23, 2024, raising approximately $1.6 million in net proceeds.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made significant progress in its clinical programs and research, it continues to operate at a loss with minimal revenue. The recent capital raise is a positive sign, but the company's financial performance remains a concern.

Positives

• The company's net loss decreased in the third quarter of 2024 compared to the same period in 2023.
• The company's cash position has improved significantly.
• The company has made significant progress in its clinical programs, including the initiation of a Phase I/II trial for lower back pain and securing FDA authorization for expanded access therapy.
• The company has achieved key milestones in its research, including the generation of human iPSC-derived Islet Cells and the development of a program using AI for biological and chemical weapon exposure.

Negatives

• The company continues to operate at a loss, with a net loss of $3.64 million for the nine months ended September 30, 2024.
• The company's revenue remains minimal, with only $8,000 generated in the first nine months of 2024.
• The company's research and development expenses have increased, reflecting the costs of ongoing clinical trials.

Risks

• The company has a limited operating history and has generated minimal revenues.
• The company's business and operations are sensitive to general business and economic conditions.
• The company has limited marketing and distribution capabilities.
• The company's industry is characterized by rapid changes in technology and customer demands.
• The company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services.
• The company may not have the capital resources to further the development of existing and/or new ones.
• Global conflicts or sanctions may impact the company's supply chain and operations.

Future Outlook

The company plans to continue advancing its clinical programs and research initiatives, including the ongoing clinical trials for Type 1 Diabetes and lower back pain. The company also intends to explore collaborations and partnerships to accelerate development. The company expects to amortize approximately $10,000 annually through 2027 related to the initial StemSpine patent costs, $46,000 annually through 2026 related to the additional StemSpine patent costs, $25,000 annually through 2027 related to the IND filing costs, and $67,000 annually through 2027 related to the additional IND filing costs. The company expects to amortize approximately $1,172 annually through 2025 related to the multipotent amniotic fetal stem cells patent costs and $25,000 annually through 2030 related to the ImmCelz patent costs.

Management Comments

• Management believes the company's ImmCelz platform has the potential to treat multiple indications due to the regenerative properties of the reprogrammed immune cells.
• Management believes the development of the iPSC cell line will save the company two to three years in research and development time.
• Management believes the AlloStem Clinical Cell Line will be useful for many of the company's programs.
• Management believes the results of independent studies show that the company will be able to substantially reduce production costs, while allowing for the manufacture of the best clinical product for patients with immune disorders.

Industry Context

The company operates in the competitive biotechnology industry, focusing on regenerative medicine and cell therapies. The company's focus on novel approaches, such as reprogramming immune cells and using iPSC technology, positions it to potentially address unmet medical needs in areas like diabetes, lower back pain, and autoimmune disorders. The company's progress in securing FDA approvals and initiating clinical trials is consistent with the industry's trend towards developing innovative therapies.

Comparison to Industry Standards

• The company's ImmCelz platform requires 75% fewer donor patient cells compared to industry standards, suggesting a more efficient process.
• The purity of the final ImmCelz product is greater than 95%, exceeding the industry standard of greater than 80%.
• The company's ImmCelz platform demonstrated a greater than 200% reduction in functional suppression of effector T cells, which is a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells.
• The company's StemSpine pilot study showed continued efficacy for treating chronic lower back pain without any serious adverse effects reported, which is a positive result compared to other treatments for chronic pain.
• The company's one-year follow-up data for CELZ-001 in Type 2 Diabetes showed an overall efficacy of 93% in treated patients demonstrating at least a 50% reduction in insulin requirement, which is a significant improvement compared to standard medical therapy.

Related Party Transactions

• The company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by a former director of the company.
• The company acquired a patent from CMH, an affiliate, for the treatment of lower back pain.
• The company purchased research tools for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the company is affiliated with.
• The CEO purchased one share of Series B Preferred Stock for $100.

Stakeholder Impact

• Shareholders may be concerned about the company's continued losses and minimal revenue.
• Employees may be encouraged by the company's progress in clinical trials and research.
• Patients may benefit from the company's development of new therapies for conditions like diabetes and lower back pain.
• Creditors may be concerned about the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to enroll patients in its ongoing clinical trials.
• The company will continue to develop its iPSC technology and explore potential applications.
• The company will seek collaborations and partnerships to accelerate development.
• The company will continue to monitor and manage its cash flow and expenses.

Key Dates

Keywords

biotechnology, stem cells, immunotherapy, clinical trials, regenerative medicine, Type 1 Diabetes, lower back pain, iPSC, FDA, Orphan Drug Designation